Merus has licensed Halozyme’s proprietary ENHANZE technology to develop and commercialize subcutaneous formulations of petosemtamab
Developed in partnership with the Johns Hopkins Applied Physics Laboratory (APL), the module is built around a multi-segment RT-PCR method with integrated indexing
This strategic initiative aims to accelerate proof-of-concept of pipeline assets by streamlining R&D operations
This is the first drug to receive a recommendation for this preventative indication in the European Union
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
This collaboration turns kitting into a strategic advantage for sponsors and sites
Diversifying its portfolio to include late-phase antiviral agent
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
Subscribe To Our Newsletter & Stay Updated
